DMPK

Across TCGA pan-cancer cohorts, DMPK Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DMPK data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher DMPK Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DMPK expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRP, SCLC, and SARC are the cancer types where DMPK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.132	0.904	<.001	36	view →
SCLC	OS	Median	All	0.155	0.722	<.001	36	view →
SARC	DFS	Median	All	0.069	0.632	<.001	12	view →
ESCA	OS	Median	All	0.022	0.701	<.001	12	view →
HNSC	OS	Median	All	0.187	0.685	.039	6	view →
STAD	DFS	Median	All	0.211	0.709	.015	3	view →
UCEC	DFS	Median	All	0.934	0.626	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DMPK–KIRP (OS)

Open the KIRP breakdown →